ストックスクリーナーアプリを入手
28.76
5.44%
1.60
前日終値:
$27.16
開ける：
$27.71
24時間の取引高:
476.93K
Relative Volume:
0.74
時価総額：
$1.65B
収益：
$87.56M
当期純損益:
$-167.47M
株価収益率:
-12.29
EPS:
-2.34
ネットキャッシュフロー:
$-148.20M
1週間 パフォーマンス:
+12.48%
1か月 パフォーマンス:
-11.99%
6か月 パフォーマンス:
-40.79%
1年 パフォーマンス:
-16.63%
1日の値動き範囲:
$27.50
$28.91
1週間の範囲:
$24.43
$28.91
52週間の値動き範囲:
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
名前
Kymera Therapeutics Inc
セクター
電話
857-285-5314
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
KYMR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
28.64 | 1.65B | 87.56M | -167.47M | -148.20M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.02 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.46 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.84 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.78 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.28 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-12-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-26 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 開始されました | Oppenheimer | Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 開始されました | Truist | Buy |
| 2023-05-05 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 開始されました | Raymond James | Mkt Perform |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-08-03 | 開始されました | Goldman | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | JP Morgan | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2021-09-30 | 開始されました | B. Riley Securities | Neutral |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-09-15 | 開始されました | BofA Securities | Neutral |
| 2020-09-15 | 開始されました | Cowen | Outperform |
| 2020-09-15 | 開始されました | Guggenheim | Buy |
| 2020-09-15 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Kymera Therapeutics Inc (KYMR) 最新ニュース
Kymera Therapeutics (KYMR) Begins Phase 1b Trial for Atopic Dermatitis Treatment | KYMR Stock News - GuruFocus
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader - The Manila Times
Breakthrough Oral Treatment for Eczema: First Patient Receives New STAT6 Degrader Drug in Clinical Trial - Stock Titan
Learn to Evaluate (KYMR) using the Charts - news.stocktradersdaily.com
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $56.36 Consensus Target Price from Analysts - Defense World
Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last? - MSN
Kymera Therapeutics Appoints Noah Goodman as Chief Business Offi - GuruFocus
Kymera Therapeutics appoints new Chief Business Officer - Investing.com Australia
Kymera Therapeutics appoints new Chief Business Officer By Investing.com - Investing.com South Africa
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer - citybiz
Strategic Power Move: Kymera Lands M&A Expert to Accelerate Drug Development Deals - Stock Titan
Kymera stock touches 52-week low at $20.77 amid market challenges - Investing.com Australia
Kymera stock touches 52-week low at $20.77 amid market challenges By Investing.com - Investing.com South Africa
Vanguard Group Inc. Raises Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
(KYMR) Trading Report - news.stocktradersdaily.com
Teacher Retirement System of Texas Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera stock touches 52-week low at $28.75 amid market challenges - Investing.com Australia
Swiss National Bank Buys 10,300 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera at H.C. Wainwright Conference: Strategic Moves in Immunology By Investing.com - Investing.com Canada
Victory Capital Management Inc. Raises Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Charles Schwab Investment Management Inc. Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Analyzing Big Cypress Acquisition (OTCMKTS:BCYP) and Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Bank of New York Mellon Corp Has $5.11 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Citigroup Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Citigroup Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - Nasdaq
Citigroup starts coverage of Kymera with $52 PT - TradingView
(KYMR) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Why Kymera Therapeutics’ Stock is Making Waves - TipRanks
Kymera at TD Cowen Conference: Focus on Clinical Advancements By Investing.com - Investing.com UK
Don't Ignore The Insider Selling In Kymera Therapeutics - Simply Wall St
Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook - Yahoo Finance
What is B. Riley’s Forecast for KYMR FY2025 Earnings? - Defense World
A Guide To The Risks Of Investing In Kymera Therapeutics Inc (KYMR) - Knox Daily
New York State Common Retirement Fund Reduces Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Financial Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Cardiff Oncology (NASDAQ:CRDF) - Defense World
Equities Analysts Offer Predictions for KYMR Q1 Earnings - Defense World
Kymera Therapeutics announces new performance-based stock plan By Investing.com - Investing.com Australia
Kymera Therapeutics COO sells $42,113 in stock By Investing.com - Investing.com South Africa
Kymera Therapeutics’ chief legal officer sells $68,239 in stock By Investing.com - Investing.com South Africa
Kymera Therapeutics CFO sells shares worth $214,219 By Investing.com - Investing.com South Africa
Kymera Therapeutics’ chief medical officer sells shares worth $174,785 By Investing.com - Investing.com Canada
Kymera Therapeutics CFO sells shares worth $214,219 - Investing.com India
Kymera Therapeutics’ chief medical officer sells shares worth $174,785 - Investing.com
Kymera Therapeutics COO sells $42,113 in stock - Investing.com
Kymera Therapeutics announces new performance-based stock plan - Investing.com India
Kymera Therapeutics Grants Performance Stock Units to Executives - TipRanks
Kymera Therapeutics Inc (KYMR) 財務データ
収益
当期純利益
現金流量
EPS
1.75%
2.22%
大文字化:
|
ボリューム (24 時間):